Journal
CANCER CELL
Volume 14, Issue 1, Pages 90-102Publisher
CELL PRESS
DOI: 10.1016/j.ccr.2008.06.004
Keywords
-
Categories
Funding
- NCI NIH HHS [NCI-CA-123823, P01 CA082566-070004, F32 CA123823, P01 CA082566, NCI-CA-082566] Funding Source: Medline
Ask authors/readers for more resources
Renal cell carcinomas (RCCs) are refractory to standard therapies. The von Hippel-Lindau (VHL) tumor suppressor gene is inactivated in 75% of RCCs. By screening for small molecules selectively targeting VHL-deficient RCC cells, we identified STF-62247. STF-62247 induces cytotoxicity and reduces tumor growth of VHL-deficient RCC cells compared to genetically matched cells with wild-type VHL. STF-62247-stimulated toxicity occurs in a HIF-independent manner through autophagy. Reduction of protein levels of essential autophagy pathway components reduces sensitivity of VHL-deficient cells to STF-62247. Using a yeast deletion pool, we show that loss of proteins involved in Golgi trafficking increases killing by STF-62247. Thus, we have found a small molecule that selectively induces cell death in VHL-deficient cells, representing a paradigm shift for targeted therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available